CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple...
Phase 2
Boston, Massachusetts, United States and 2 other locations
This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. ...
Phase 2
Boston, Massachusetts, United States and 5 other locations
of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple...
Phase 2
Boston, Massachusetts, United States and 7 other locations
This research study is studying a targeted therapy as a possible treatment for multiple myeloma.The names of the study drugs involv...
Phase 1
Boston, Massachusetts, United States and 1 other location
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
Boston, Massachusetts, United States and 24 other locations
a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple...
Phase 1
Boston, Massachusetts, United States and 4 other locations
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple...
Phase 2
Boston, Massachusetts, United States and 5 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Boston, Massachusetts, United States and 48 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Boston, Massachusetts, United States and 40 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
Boston, Massachusetts, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal